ArticleFrontiers in cellular and infection microbiology2026
HBx interacts with the host YBX3 protein and up-regulates its expression to mediate efficient Hepatitis B viral replication.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Hepatitis B (CHB) remains a global health challenge, and identifying the precise viral-host interactions that sustain the viral life cycle is essential for developing next-generation therapeutic strategies. In this study, we identify the host factor YBX3 (Y-box binding protein 3) as a critical requirement for efficient Hepatitis B Virus (HBV) replication. Methods: Using immunoprecipitation-coupled mass spectrometry, we identified YBX3 as a novel interactor of the HBV regulatory protein, HBx. This interaction was validated via co-immunoprecipitation. The functional role of YBX3 was characterized using CRISPR/Cas9-mediated knockout in HepG2-hNTCP cells, followed by genetic rescue experiments. Viral fitness was assessed by quantifying cccDNA, pgRNA, HBsAg, HBeAg, and extracellular HBV DNA. Subcellular fractionation was employed to determine the distribution of YBX3 and HBx. Results: YBX3 interacts specifically with HBx via its C-terminal domain. Genetic ablation of YBX3 drastically impaired HBV replication, resulting in a significant reduction in viral DNA, HBeAg, and HBsAg, a phenotype significantly reversed by YBX3 re-expression. Subcellular fractionation confirmed that both proteins are predominantly nuclear and that HBx expression upregulates YBX3 abundance in both nuclear and cytoplasmic fractions. YBX3 mRNA and protein levels were significantly upregulated during active HBV infection, suggesting a proviral feedback loop. Conclusion: YBX3 is a novel proviral host factor that drives efficient HBV replication by binding to HBx. This interaction likely supports the crucial nuclear functions of HBx that are vital for efficient viral replication. These findings establish YBX3 as a compelling new target for antiviral therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.